AIIMS Validates Indigenous Stroke Device Matching International Standards in Clinical Trial

AIIMS conducted a multi‑center clinical trial of a domestically developed stroke intervention device, evaluating its safety, imaging quality, and clot‑removal efficiency against benchmark foreign equipment to determine suitability for national hospitals across several leading tertiary hospitals.

Device achieved imaging resolution and procedural speed that were statistically indistinguishable from those of leading imported stroke devices, a finding confirmed by the institute’s neurology experts who reviewed the trial’s quantitative results and meet regulatory standards.

Patients enrolled in the study experienced no serious complications, and their functional recovery scores aligned with outcomes reported in prior international research, indicating the home‑grown device delivers comparable clinical benefits and no additional hospitalization required.

Healthcare officials anticipate that adopting this proven indigenous technology will cut reliance on expensive imports, lower overall treatment costs for stroke care, and stimulate domestic manufacturing capabilities, supporting broader goals of medical self‑sufficiency and improve patient access in remote regions.